ReviewSignal transduction and targeted therapy2022
Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics.
Review in Signal transduction and targeted therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 759 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
759 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,266 citations in OpenAlex.
- The gut-prostate axis in benign prostatic hyperplasia: systematic review of microbial dysbiosis and pathogenic mechanisms.BMC urology · 2026Pooled it
- Dual anti-pseudomonal and resistance-modulatory actions ofPharmaceutical biology · 2026Article
- Multifaceted effects ofVirulence · 2026Article
- Design, synthesis, and antibacterial activity study of pyrroloquinazoline diamine derivatives.Journal of enzyme inhibition and medicinal chemistry · 2026Article
- Small regulatory RNAs mediated regulation of virulence and host-pathogen interaction in the Gram-negative ESKAPE pathogens.Virulence · 2026Review
- High resolution cryo-EM structure of theJournal of structural biology: X · 2026Article
- Fish gut-water interface as a hotspot for the dissemination of antibiotic resistance genes across natural and aquaculture systems.Current research in microbial sciences · 2026Article
- Identification of DksA as a novel pro-inflammatory mediator ofVirulence · 2026Article
- A dual-action bacteriophage protein Ped1 degrades DNA and blocks replication in Pseudomonas aeruginosa.The EMBO journal · 2026Article
- Evaluation of Probiotic Properties and Antimicrobial Substances Produced by Five Lactic Acid Bacteria Against Foodborne and Spoilage Pathogens.MicrobiologyOpen · 2026Article
- MiR-342-3p Attenuates Inflammation and Pyroptosis in Severe Community-Acquired Pneumonia by Targeting EP300.Biochemical genetics · 2026Article
- Advances in DNA nanostructures for pathogenic microorganisms.Materials today. Bio · 2026Review
- Green synthesis of a manganese oxide-selenium nanocomposite using watermelon peel waste with antimicrobial and mosquitocidal activities.RSC advances · 2026Article
- A functional screen for bacterial ubiquitin regulation identifies an unusual Pseudomonas aeruginosa E3 ligase.The EMBO journal · 2026Article
- Virulence arsenal and antibiotic resistance backgrounds in Pseudomonas aeruginosa isolates from hospital wastewater samples from Iraq.Molecular biology reports · 2026Article
- Pseudomonas aeruginosa induces the generation of pathogenic IFNγNature microbiology · 2026Article
- Molecular Insight into the Inhibition ofACS omega · 2026Article
- Healing potential of curcumin gel in experimental wounds infected with resistant Pseudomonas aeruginosa: a comparative study with silver sulfadiazine.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Microbial adhesion promotes Piezo1 activation to initiate innate immunity.Nature immunology · 2026Article
- Bacteriocins as Alternative Antimicrobial Agents for Wound-Associated Infections: Mechanisms, Activity Against Biofilms and Translational Potential.Antibiotics (Basel, Switzerland) · 2026Review
699 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
Abstract
Pseudomonas aeruginosa (P. aeruginosa) is a Gram-negative opportunistic pathogen that infects patients with cystic fibrosis, burn wounds, immunodeficiency, chronic obstructive pulmonary disorder (COPD), cancer, and severe infection requiring ventilation, such as COVID-19. P. aeruginosa is also a widely-used model bacterium for all biological areas. In addition to continued, intense efforts in understanding bacterial pathogenesis of P. aeruginosa including virulence factors (LPS, quorum sensing, two-component systems, 6 type secretion systems, outer membrane vesicles (OMVs), CRISPR-Cas and their regulation), rapid progress has been made in further studying host-pathogen interaction, particularly host immune networks involving autophagy, inflammasome, non-coding RNAs, cGAS, etc. Furthermore, numerous technologic advances, such as bioinformatics, metabolomics, scRNA-seq, nanoparticles, drug screening, and phage therapy, have been used to improve our understanding of P. aeruginosa pathogenesis and host defense. Nevertheless, much remains to be uncovered about interactions between P. aeruginosa and host immune responses, including mechanisms of drug resistance by known or unannotated bacterial virulence factors as well as mammalian cell signaling pathways. The widespread use of antibiotics and the slow development of effective antimicrobials present daunting challenges and necessitate new theoretical and practical platforms to screen and develop mechanism-tested novel drugs to treat intractable infections, especially those caused by multi-drug resistance strains. Benefited from has advancing in research tools and technology, dissecting this pathogen's feature has entered into molecular and mechanistic details as well as dynamic and holistic views. Herein, we comprehensively review the progress and discuss the current status of P. aeruginosa biophysical traits, behaviors, virulence factors, invasive regulators, and host defense patterns against its infection, which point out new directions for future investigation and add to the design of novel and/or alternative therapeutics to combat this clinically significant pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.